<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Diffusion Pharmaceuticals</title>
	<atom:link href="http://www.diffusionpharma.com/feed" rel="self" type="application/rss+xml" />
	<link>http://www.diffusionpharma.com</link>
	<description></description>
	<lastBuildDate>Mon, 02 Aug 2010 14:30:18 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.1</generator>
		<item>
		<title>Diffusion Pharmaceuticals Announces Issuance of New U.S. Patent</title>
		<link>http://www.diffusionpharma.com/progress/diffusion-pharmaceuticals-announces-issuance-of-new-u-s-patent</link>
		<comments>http://www.diffusionpharma.com/progress/diffusion-pharmaceuticals-announces-issuance-of-new-u-s-patent#comments</comments>
		<pubDate>Mon, 02 Aug 2010 14:00:17 +0000</pubDate>
		<dc:creator>tlinkous</dc:creator>
				<category><![CDATA[Awards]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Progress]]></category>
		<category><![CDATA[first-in-class drugs]]></category>
		<category><![CDATA[hypoxia]]></category>
		<category><![CDATA[TSC]]></category>
		<category><![CDATA[US patent issued]]></category>

		<guid isPermaLink="false">http://www.diffusionpharma.com/?p=251</guid>
		<description><![CDATA[CHARLOTTESVILLE, VA –August 2, 2010 – Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,759,506 entitled “Bipolar Trans Carotenoid Salts and Their Uses.” This patent includes drug formulation and use claims relating to Diffusion’s entire family of first-in-class new chemical entities. [...]]]></description>
		<wfw:commentRss>http://www.diffusionpharma.com/progress/diffusion-pharmaceuticals-announces-issuance-of-new-u-s-patent/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Diffusion Pharmaceuticals LLC Wins Inaugural Perfect Pitch Competition –Biotech Investment Challenge –at BioNetwork East Conference in Miami, FL</title>
		<link>http://www.diffusionpharma.com/uncategorized/diffusion-pharmaceuticals-llc-wins-inaugural-perfect-pitch-competition-%e2%80%93biotech-investment-challenge-%e2%80%93at-bionetwork-east-conference-in-miami-fl</link>
		<comments>http://www.diffusionpharma.com/uncategorized/diffusion-pharmaceuticals-llc-wins-inaugural-perfect-pitch-competition-%e2%80%93biotech-investment-challenge-%e2%80%93at-bionetwork-east-conference-in-miami-fl#comments</comments>
		<pubDate>Mon, 22 Mar 2010 18:19:29 +0000</pubDate>
		<dc:creator>tlinkous</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://www.diffusionpharma.com/?p=181</guid>
		<description><![CDATA[Charlottesville, VA — March 22, 2010 —Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat serious or life-threatening unmet medical conditions, today announced its selection as the winner of the Perfect Pitch Competition – Biotech Investment Challenge. The winner was announced during a special awards ceremony attended by over 150 delegates and [...]]]></description>
		<wfw:commentRss>http://www.diffusionpharma.com/uncategorized/diffusion-pharmaceuticals-llc-wins-inaugural-perfect-pitch-competition-%e2%80%93biotech-investment-challenge-%e2%80%93at-bionetwork-east-conference-in-miami-fl/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Diffusion Pharmaceuticals LLC Announces Publication of Three Studies Testing Trans Sodium Crocetinate (TSC); Statistically significant results seen in animal models of primary brain cancer, cerebral ischemia and stroke</title>
		<link>http://www.diffusionpharma.com/uncategorized/diffusion-pharmaceuticals-llc-announces-publication-of-three-studies-testing-trans-sodium-crocetinate-tsc-statistically-significant-results-seen-in-animal-models-of-primary-brain-cancer-cerebral-i</link>
		<comments>http://www.diffusionpharma.com/uncategorized/diffusion-pharmaceuticals-llc-announces-publication-of-three-studies-testing-trans-sodium-crocetinate-tsc-statistically-significant-results-seen-in-animal-models-of-primary-brain-cancer-cerebral-i#comments</comments>
		<pubDate>Tue, 23 Feb 2010 19:44:09 +0000</pubDate>
		<dc:creator>tlinkous</dc:creator>
				<category><![CDATA[Presentations]]></category>
		<category><![CDATA[Progress]]></category>
		<category><![CDATA[Research]]></category>
		<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://www.diffusionpharma.com/?p=174</guid>
		<description><![CDATA[Charlottesville, VA –February 23, 2010 – Diffusion Pharmaceuticals LLC today announced that three separate preclinical studies testing its lead drug candidate trans sodium crocetinate, (TSC), have been published in peer-reviewed journals during the last six months. These studies demonstrate that TSC improves tissue oxygenation in hypoxic brain tumor tissue, exerts a neuroprotective effect against ischemic [...]]]></description>
		<wfw:commentRss>http://www.diffusionpharma.com/uncategorized/diffusion-pharmaceuticals-llc-announces-publication-of-three-studies-testing-trans-sodium-crocetinate-tsc-statistically-significant-results-seen-in-animal-models-of-primary-brain-cancer-cerebral-i/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
